amiselimod vs ozanimod

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline

amiselimod

Developed by Bausch Health under a licence from Tanabe Pharma Corporation

Phase 2 in Ulcerative ColitisSmall molecule (oral S1P receptor modulator)
Reliable signal

NCT04857112 · Phase 2 · completed

This trial randomly assigned 322 people with ulcerative colitis to one of two amiselimod doses or placebo, with participants and investigators unaware of assignment. The primary measure was change in the modified Mayo Score, which combines the appearance of the bowel lining at endoscopy with clinical disease activity. Scores fell by 2.3 points on amiselimod against 1.6 points on placebo (p=0.002).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Change from Baseline in the modified Mayo Score at Day 85 (Baseline to Day 85): Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002) (met)

Result source: NCT04857112

ozanimod · Zeposia

Marketed by Bristol-Myers Squibb and partners

Approved in Ulcerative ColitisSmall molecule (S1P1,5 modulator)
Reliable signal

NCT02435992 · Phase 3 · completed

Randomized, quadruple-blinded, placebo-controlled, large adequately powered Phase 3 trial (n=1012) with a hard clinical/endoscopic remission endpoint that achieved statistical significance in the favorable direction at both induction and maintenance timepoints, satisfying the 'strong' definition.

Next expected readout: July 2032 · NCT05076175 (registry estimate)

Reported efficacy

Percentage of Participants in Clinical Remission at 10 Weeks; Percentage of Participants in Clinical Remission at 52 Weeks: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period)) (met)

Result source: NCT02435992

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointamiselimodozanimod
Clinical remission (induction)—Not reported18.4% vs 6%+12.4 vs placebowk 10 · n 429NCT02435992
3 other results
  • 21% vs 6% wk 10 · n 367 · Phase 3 · primary NCT02435992
  • 16.4% vs 6.2% 1 mg · wk 8 · n 67 · Phase 2 · primary NCT01647516
  • 13.8% vs 6.2% 0.5 mg · wk 8 · n 65 · Phase 2 · primary NCT01647516
Clinical remission (maintenance)—Not reported37% vs 18.5%+18.5 vs placebowk 52 · n 230NCT02435992
2 other results
  • 20.9% vs 6.2% 1 mg · wk 32 · n 67 · Phase 2 · secondary NCT01647516
  • 26.2% vs 6.2% 0.5 mg · wk 32 · n 65 · Phase 2 · secondary NCT01647516
Clinical response (induction)—Not reported47.8% vs 25.9%+21.9 vs placebowk 10 · n 429NCT02435992
3 other results
  • 52.6% vs 25.9% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 56.7% vs 36.9% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 53.8% vs 36.9% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516
Endoscopic improvement (induction)—Not reported27.3% vs 11.6%+15.7 vs placebowk 10 · n 429NCT02435992
3 other results
  • 27.2% vs 11.6% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 34.3% vs 12.3% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 27.7% vs 12.3% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516
Corticosteroid-free remission (maintenance)—Not reported31.7% vs 16.7%+15 vs placebowk 52 · n 230NCT02435992

Clinical remission (induction)

amiselimod
—Not reported
ozanimod
18.4% vs 6%+12.4 vs placebowk 10 · n 429NCT02435992
3 other results
  • 21% vs 6% wk 10 · n 367 · Phase 3 · primary NCT02435992
  • 16.4% vs 6.2% 1 mg · wk 8 · n 67 · Phase 2 · primary NCT01647516
  • 13.8% vs 6.2% 0.5 mg · wk 8 · n 65 · Phase 2 · primary NCT01647516

Clinical remission (maintenance)

amiselimod
—Not reported
ozanimod
37% vs 18.5%+18.5 vs placebowk 52 · n 230NCT02435992
2 other results
  • 20.9% vs 6.2% 1 mg · wk 32 · n 67 · Phase 2 · secondary NCT01647516
  • 26.2% vs 6.2% 0.5 mg · wk 32 · n 65 · Phase 2 · secondary NCT01647516

Clinical response (induction)

amiselimod
—Not reported
ozanimod
47.8% vs 25.9%+21.9 vs placebowk 10 · n 429NCT02435992
3 other results
  • 52.6% vs 25.9% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 56.7% vs 36.9% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 53.8% vs 36.9% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516

Endoscopic improvement (induction)

amiselimod
—Not reported
ozanimod
27.3% vs 11.6%+15.7 vs placebowk 10 · n 429NCT02435992
3 other results
  • 27.2% vs 11.6% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 34.3% vs 12.3% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 27.7% vs 12.3% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516

Corticosteroid-free remission (maintenance)

amiselimod
—Not reported
ozanimod
31.7% vs 16.7%+15 vs placebowk 52 · n 230NCT02435992
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. amiselimod: 0 of 4 rows · ozanimod: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricamiselimodozanimod
Dropout rate—
—1mga
NCT02435992 · Phase 3 · monotherapy
show 15 more results
—1mg
NCT02435992 · Phase 3 · monotherapy
—1mg
NCT02435992 · Phase 3 · monotherapy
—RPC1063 (Maintenance Period)
NCT02435992 · Phase 3 · monotherapy
11.7%RPC1063 Cohort 2 (Induction Period
NCT02435992 · Phase 3 · monotherapy
46.3%RPC01-202 Ozanimod Open Label
NCT02531126 · Phase 3 · monotherapy
69.5%RPC01-3101 Ozanimod-Ozanimod
NCT02531126 · Phase 3 · monotherapy
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
6%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg/1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
4.5%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—Open-Label Treatment Period (OLP):
NCT01647516 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs—
—1mga
NCT02435992 · Phase 3 · monotherapy
show 15 more results
—1mg
NCT02435992 · Phase 3 · monotherapy
—1mg
NCT02435992 · Phase 3 · monotherapy
—RPC1063 (Maintenance Period)
NCT02435992 · Phase 3 · monotherapy
3.3%RPC1063 Cohort 2 (Induction Period
NCT02435992 · Phase 3 · monotherapy
7.4%RPC01-202 Ozanimod Open Label
NCT02531126 · Phase 3 · monotherapy
6.1%RPC01-3101 Ozanimod-Ozanimod
NCT02531126 · Phase 3 · monotherapy
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg/1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
3%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—Open-Label Treatment Period (OLP):
NCT01647516 · Phase 2 · registry result, not featured evidence
Serious AEs—
4%1mga
NCT02435992 · Phase 3 · monotherapy
show 15 more results
6.3%1mg
NCT02435992 · Phase 3 · monotherapy
5.2%1mg
NCT02435992 · Phase 3 · monotherapy
—RPC1063 (Maintenance Period)
NCT02435992 · Phase 3 · monotherapy
—RPC1063 Cohort 2 (Induction Period
NCT02435992 · Phase 3 · monotherapy
14.8%RPC01-202 Ozanimod Open Label
NCT02531126 · Phase 3 · monotherapy
17.2%RPC01-3101 Ozanimod-Ozanimod
NCT02531126 · Phase 3 · monotherapy
3%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
2.4%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
18.6%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
1.5%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
0%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
25%0.5 mg/1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
9.1%Open-Label Treatment Period (OLP):
NCT01647516 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs—
1mga
anaemia 3.5% (placebo 6%)
NCT02435992 · Phase 3 · monotherapy
show 11 more results
1mg
anaemia 4.1% (placebo 6%)
NCT02435992 · Phase 3 · monotherapy
1mg
anaemia 0.9% (placebo 6%)
NCT02435992 · Phase 3 · monotherapy
covid-19 25.9% (placebo 16.8%)
lymphopenia 16.7% (placebo 17.3%)
leukopenia 7.4% (placebo 4.1%)
NCT02531126 · Phase 3 · monotherapy
lymphopenia 16.3% (placebo 17.3%)
covid-19 11.3% (placebo 16.8%)
lymphocyte count decreased 10.8% (placebo 12.8%)
NCT02531126 · Phase 3 · monotherapy
1 mg
alanine aminotransferase increased 3% (placebo 0%)
headache 3% (placebo 4.6%)
anaemia 1.5% (placebo 6.2%)
NCT01647516 · Phase 2 · registry result, not featured evidence
1 mg
alanine aminotransferase increased 2.4% (placebo 0%)
colitis ulcerative 2.4% (placebo 1.5%)
anaemia 0% (placebo 6.2%)
NCT01647516 · Phase 2 · registry result, not featured evidence
1 mg
hypertension 11.9% (placebo 0%)
gamma-glutamyltransferase increased 8.5% (placebo 0%)
upper respiratory tract infection 8.5% (placebo 3.1%)
NCT01647516 · Phase 2 · registry result, not featured evidence
0.5 mg
anaemia 6.2% (placebo 6.2%)
colitis ulcerative 3.1% (placebo 1.5%)
back pain 1.5% (placebo 1.5%)
NCT01647516 · Phase 2 · registry result, not featured evidence
0.5 mg
alanine aminotransferase increased 2.8% (placebo 0%)
nasopharyngitis 2.8% (placebo 0%)
anaemia 0% (placebo 6.2%)
NCT01647516 · Phase 2 · registry result, not featured evidence
0.5 mg/1 mg
anaemia 5.4% (placebo 6.2%)
gamma-glutamyltransferase increased 5.4% (placebo 0%)
lymphocyte count decreased 5.4% (placebo 0%)
NCT01647516 · Phase 2 · registry result, not featured evidence
anaemia 7.3% (placebo 6.2%)
colitis ulcerative 7.3% (placebo 1.5%)
bronchitis 5.5% (placebo 0%)
NCT01647516 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

amiselimod

Mayo 9 -2.3 vs -1.6 placebo score @ 12.142857wk
absolute change · score
NCT04857112 · Phase 2 · sponsor-reported, not registry data

ozanimod

Clinical Remission 16.4% (n=67) vs 6.2% (n=65) placebo @ 8wk1 mg
responder rate · % of participants
NCT01647516 · Phase 2 · registry result, not featured evidence
show 6 more results
20.9% (n=67) vs 6.2% (n=65) placebo @ 32wk1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
13.8% (n=65) vs 6.2% (n=65) placebo @ 8wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
26.2% (n=65) vs 6.2% (n=65) placebo @ 32wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
18.4% (n=429) vs 6% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
21% (n=367) vs 6% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
37% (n=230) vs 24.6% (n=69) placebo @ 52wk
NCT02435992 · Phase 3 · monotherapy
Clinical Response 56.7% (n=67) vs 36.9% (n=65) placebo @ 8wk1 mg
responder rate · % of participants
NCT01647516 · Phase 2 · registry result, not featured evidence
show 6 more results
50.7% (n=67) vs 20% (n=65) placebo @ 32wk1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
53.8% (n=65) vs 36.9% (n=65) placebo @ 8wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
35.4% (n=65) vs 20% (n=65) placebo @ 32wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
47.8% (n=429) vs 25.9% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
52.6% (n=367) vs 25.9% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
60% (n=230) vs 39.1% (n=69) placebo @ 52wk
NCT02435992 · Phase 3 · monotherapy
Endoscopic Improvement 34.3% (n=67) vs 12.3% (n=65) placebo @ 8wk1 mg
responder rate · % of participants
NCT01647516 · Phase 2 · registry result, not featured evidence
show 6 more results
32.8% (n=67) vs 12.3% (n=65) placebo @ 32wk1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
27.7% (n=65) vs 12.3% (n=65) placebo @ 8wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
32.3% (n=65) vs 12.3% (n=65) placebo @ 32wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
27.3% (n=429) vs 11.6% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
27.2% (n=367) vs 11.6% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
45.7% (n=230) vs 29% (n=69) placebo @ 52wk
NCT02435992 · Phase 3 · monotherapy
Mucosal Healing 12.6% (n=429) vs 3.7% (n=216) placebo @ 10wk
responder rate · % of participants
NCT02435992 · Phase 3 · monotherapy
show 2 more results
11.4% (n=367) vs 3.7% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
29.6% (n=230) vs 10.1% (n=69) placebo @ 52wk
NCT02435992 · Phase 3 · monotherapy
Corticosteroid-free Clinical Remission 31.7% (n=230) vs 24.6% (n=69) placebo @ 52wk
responder rate · % of participants
NCT02435992 · Phase 3 · monotherapy
Durable Clinical Remission 17.8% (n=230) vs 7.2% (n=69) placebo @ 52wk
responder rate · % of participants
NCT02435992 · Phase 3 · monotherapy
Clinical Remission 44% (n=266) vs 41.6% (n=113) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 4 more results
50.5% (n=266) vs 57.8% (n=113) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
50.9% (n=266) vs 59.4% (n=113) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
54.7% (n=266) vs 39.1% (n=113) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
54.5% (n=266) vs 38.5% (n=113) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Clinical Response 77% (n=261) vs 81.8% (n=110) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 4 more results
83.9% (n=261) vs 84.1% (n=110) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
87.6% (n=261) vs 89.6% (n=110) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
86.4% (n=261) vs 82.2% (n=110) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
90.1% (n=261) vs 74.4% (n=110) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Endoscopic Improvement 49.7% (n=290) vs 51.2% (n=121) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 9 more results
41.4% (n=30) vs 51.2% (n=121) placebo @ 46wk
NCT02531126 · Phase 3 · monotherapy
58.6% (n=290) vs 60.6% (n=121) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
50% (n=30) vs 60.6% (n=121) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
60.8% (n=290) vs 61.1% (n=121) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
57.7% (n=30) vs 61.1% (n=121) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
62.5% (n=290) vs 49.1% (n=121) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
56.3% (n=30) vs 49.1% (n=121) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
60.9% (n=290) vs 43.5% (n=121) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
100% (n=30) vs 43.5% (n=121) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Corticosteroid-free Clinical Remission 38% (n=266) vs 40.7% (n=113) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 4 more results
41.6% (n=266) vs 52.2% (n=113) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
45.1% (n=266) vs 55.1% (n=113) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
47.3% (n=266) vs 37% (n=113) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
48.2% (n=266) vs 38.5% (n=113) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Histologic Remission 25.4% (n=276) vs 19.4% (n=108) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 9 more results
48.1% (n=30) vs 19.4% (n=108) placebo @ 46wk
NCT02531126 · Phase 3 · monotherapy
32.8% (n=276) vs 22.6% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
26.7% (n=30) vs 22.6% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
32.4% (n=276) vs 32.9% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
48% (n=30) vs 32.9% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
47.5% (n=276) vs 42.9% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
62.5% (n=30) vs 42.9% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
56.1% (n=276) vs 34.1% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
100% (n=30) vs 34.1% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Mucosal Healing 20.4% (n=276) vs 14.8% (n=108) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 9 more results
25.9% (n=30) vs 14.8% (n=108) placebo @ 46wk
NCT02531126 · Phase 3 · monotherapy
28% (n=276) vs 19% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
20% (n=30) vs 19% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
27.4% (n=276) vs 32.8% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
44% (n=30) vs 32.8% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
43.9% (n=276) vs 32.7% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
37.5% (n=30) vs 32.7% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
46.3% (n=276) vs 26.8% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
100% (n=30) vs 26.8% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy

+ 6 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amiselimod's landscape · ozanimod's landscape